Computational POM and DFT evaluation of experimental in-vitro cancer inhibition of staurosporine-ruthenium(II) complexes: The power force of organometallics in drug design
Publication Type
Original research
Authors
Fulltext
Download

A computational Petra/Osiris/Molinspiration/DFT(POM/DFT) based model has been developed for the identification of physico-chemical parameters governing the bioactivity of ruthenium-staurosporine complexes 2-4 containing an antitumoral-kinase (TK) pharmacophore sites. The four compounds 1-4 analyzed here were previously screened for their antitumor activity, compounds 2 and 4 are neutral, whereas analogue compound 3 is a monocation with ruthenium(II) centre. The highest anti-antitumor activity was obtained for compounds 3 and 4, which exhibited low IC50 values (0.45 and 8 nM, respectively), superior to staurosporine derivative (pyridocarbazole ligand 1, 150·103 nM). The IC50 of 3 (0.45 nM), represents 20,000 fold increased activity as compared to staurosporine derivative 1. The increase of bioactivity could be attributed to the existence of pi-charge transfer from metal-staurosporine to its (COδ-NHδ +) antitumor pharmacophore site.

Journal
Title
Acta Chimica Slovenica
Publisher
Slovensko Kemijsko Drustvo
Publisher Country
Slovenia
Indexing
Thomson Reuters
Impact Factor
1.104
Publication Type
Prtinted only
Volume
62
Year
2015
Pages
679-688